SciELO - Scientific Electronic Library Online

 
vol.147 número11Niveles de colesterol no HDL en la población chilena y su asociación con enfermedad cardiovascular y diabetes mellitus: estudio de corte transversal en Encuesta Nacional de Salud 2009-2010La derivación protocolizada a endoscopía asociada a la detección de Helicobacter pylori mediante antígeno en deposiciones disminuye lista de espera para endoscopía y optimiza la detección de lesiones pre-malignas y cáncer gástrico incipiente índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

PENA, CAMILA et al. Prognostic impact of renal failure recovery in patients with newly diagnosed multiple mieloma. Rev. méd. Chile [online]. 2019, vol.147, n.11, pp.1374-1381. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872019001101374.

Background

Renal failure (RF) is a common complication in patients with newly diagnosed multiple myeloma (NDMM).

Aim

To evaluate the frequency of RF in NDMM patients, and the prognostic impact of its reversibility.

Material and Methods

A retrospective study evaluating demographic and clinical characteristics of 154 consecutive patients with NDMM was carried out. Estimated glomerular filtration rate (eGFR) was calculated at the beginning and at the end of the induction therapy. In addition, we evaluated renal responses (RR) according to the International Myeloma Working Group (IMWG) criteria. The induction regimen was based on thalidomide in all cases.

Results

Fifty-three patients had RF (34.4%). Complete renal response (RR) was achieved in 51%. Three years overall survival in patients without RF, with RF and complete RR, and patients with RF and any other RR, was 66, 47 and 13%, respectively. Median survival was 53, 27 and 6 months, respectively (p < 0.01). In the multivariate analysis, RF and hypercalcemia were independent predictors of a worse outcome.

Conclusions

Achieving a complete RR in patients with NDMM, is associated with a better survival.

Palabras clave : Bortezomib; Kidney; Multiple Myeloma; Renal Insufficiency.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )